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ABSTRACT
Cancer is genetically heterogeneous regarding to molecular genetic characteristics 
and pathogenic pathways. A wide spectrum of biomarkers, including DNA markers, 
is used in determining genomic instability, molecular subtype determination and 
disease prognosis, and estimating sensitivity to different drugs in clinical practice. 
In a previous study, we developed highly effective DNA markers using improved 
random amplified polymorphic DNA (RAPD) with high-GC primers, which is a valuable 
approach for the genetic authentication of medicinal plants. In this study, we applied 
this effective DNA marker technique to generate genetic fingerprints that detect 
genomic alterations in human breast cancer tissues and then developed sequence-
characterized amplified region (SCAR) markers. Three SCAR markers (BC10-1, BC13-
4 and BC31-2) had high levels of genomic DNA amplification in breast cancer. The 
PHKG2 and RNF40 genes are either overlapping or close to the sequences of SCAR 
marker BC13-4, while SCAR marker BC10-1 is in the intron and overlap the DPEP1 
gene, suggesting that alterations in the expression of these genes could contribute 
to cancer progression. Screening of breast cancer cell lines showed that the mRNA 
expression levels for the PHKG2 and DPEP1 were lower in non-tumorigenic mammary 
epithelial cell MCF10A, but elevated in other cell lines. The DPEP1 mRNA level in 
invasive ductal carcinoma specimens was significantly higher than that of the adjacent 
normal tissues in women. Taken together, high-GC RAMP-PCR provides greater 
efficacy in measuring genomic DNA amplifications, deletion or copy number variations. 
Furthermore, SCAR markers BC10-1 and BC13-4 might be useful diagnostic markers 
for breast cancer carcinomas.
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INTRODUCTION
Breast cancer (BC) has the highest incidence of 
cancer occurrence in the female population and is the 
number one cause of cancer deaths for women worldwide 
[1–5]. In 2017, there were 252,710 estimated new cases of 
BC and 40,610 expected BC deaths among women in the 
United States [1]. Resource-stratified guidelines provide a 
vehicle for designing programs to promote early detection, 
diagnosis, and treatment using existing infrastructure and 
renewable resources and methods. Existing strategies for 
evaluating the current state and projecting future burden 
have a major role in developing new strategies to improve 
BC outcomes at the national and international levels 
[6–8]. While China’s mainland currently has 470,000 
BC patients, only 20 percent of them were diagnosed at 
early stage, whereas, in USA, 80 percent of BC patients 
were diagnosed at an early stage, securing best practice 
and best outcome for the patients (http://www.chinadaily.
com.cn/china/2012–03/12/content_14814002.htm). Thus, 
we must increase BC risk awareness in the general public 
by recommending regular screening starting at 40 years of 
age to promote early detection and treatment. 
Cancer is genetically heterogeneous regarding to 
molecular characteristics and pathogenic pathways. A wide 
spectrum of biomarkers, including DNA markers, is used 
for determining genomic instability, molecular subtype 
determination, and prognosis, and estimating sensitivity to 
different drugs in practice. Systematic analysis of genetic 
changes in colon cancer development demonstrated 
that multiple mutations are necessary for the evolution 
of normal cells into cancer cells [9]. There is growing 
evidence that multiple mutations are responsible for the 
development of cancer; cancer cells must exhibit mutator 
phenotypes [10, 11], which are likely to be responsible for 
the genomic instability found in cancer tissues. Mutator 
phenotype, including defective mismatch repair, is 
known to cause microsatellite instability, associated with 
multiple hereditary cancers [12, 13]. Loss of chromosomal 
materials would inactivate tumor suppressor genes while 
gain of chromosomal materials has the potential to activate 
tumor-promoting genes [8]. Genomic instability and 
chromosome copy number variations are the hallmarks 
of neoplastic transformation and a herald of genomic 
damage, leading to the conclusion that multiple mutations 
are the driving force in the carcinogenic processes [14–
16]. Thus, the development of diagnostic markers for BC 
is vital for early detection and treatment of BC patients.
Since the 1990s, a number of genetic and DNA-
based molecular marker techniques have been developed, 
including random amplified polymorphic DNA (RAPD) 
[17, 18]. Since then, RAPD technique either alone or in 
combination with other techniques is widely used for the 
genetic characterization of different medicinal plants, 
and other organisms [18, 19]. Although RAPD has few 
requirements of the amount of template DNA, produces no 
hazardous contamination, and is simple and inexpensive, the 
few disadvantages that poses including poor reproducibility 
and low production or yield. Resolution and production 
of RAPD are greatly increased by prolonging the RAMP 
time from the stage of annealing to extension in PCR [18, 
19]. To improve the effectiveness of the RAPD method, we 
developed a highly effective DNA marker technique using 
improved RAPD with high-GC content primers, in which 
the GC content reaches 8–10 nucleotides for a 10 nucleotide 
primer (80~100%) [20,21]. The Sequence Characterized 
Amplified Region (SCAR) markers are very stable, 
sensitive, and reliable. These markers are also effective for 
diagnostic purposes by using a simple PCR assay, which 
are generally derived from the molecular cloning of RAPD 
fragments in medicinal plants [21–28]. 
Different types of cancers have been associated 
with abnormal DNA fingerprinting; therefore, in this 
study we applied this effective improved RAPD technique 
to generate genetic fingerprints that detect genomic 
alterations in human breast cancer and develop diagnostic 
SCAR markers. 
RESULTS
RAPD amplification from breast tumor tissue 
DNA samples using high-GC primers
To increase the efficiency of RAPD amplification 
and obtain more specific bands, standard primers were 
replaced with high-GC content primers (FY-10, FY-13 
and FY-32). In addition, the RAMP time from the stage of 
annealing (36ºC) to extension (72ºC) was set to 5% (0.125 
ºC/s). This improved RAPD was used to amplify genomic 
DNA from five breast cancer patients. For each patient, 
two tissue samples were obtained from both the tumor and 
the normal tissue adjacent to the tumor. The PCR products 
were resolved by electrophoresis on a 1.5% agarose gel 
and showed signal difference in intensity of RAPD bands 
within patients (Figure 1).
Cloning and sequencing of DNA fragments 
Three different bright bands with over-amplification 
in Figure 1 were excised and purified from the agarose 
gel for cloning into the pGM-T vector (Figure 2A). The 
positive cloned DNA fragments, 10-1, 13-4 and 31-2 
(Figure 2B–2D) were selected based on insert sizes by 
EcoRI digestion matching those of the RAPD fragments in 
Figure 1 and Figure 2A and then sequenced by the Sanger 
method. Sequence homology was determined using the 
online program BLAST (http://www.ncbi.nlm.nih.gov/
BLAST/) against the GenBank database.
Sequencing of the aforementioned three cloned 
RAPD fragments from human breast cancer tissue 
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revealed that clone 10-1 consisted of 1027 nucleotides is 
located in the intron of DPEP1 transcript variant 2, and 
overlapped DPEP1 (dipeptidase 1) transcript variant 1 in 
GenBank (NM_004413) (Figure 3A and Figure 4A). Clone 
13-4 consisted of 663 nucleotides (Figure 3B), located 
only 536 bp away from the PHKG2 gene (Homo sapiens 
phosphorylase kinase, gamma 2, NM_000294) (Homo 
sapiens chromosome 16, GRCh38 Primary Assembly. 
Sequence ID: ref|NC_000016.10|Length: 90338345, 
Range of clone13-4: 30761532 to 30762194 vs Range of 
PHKG2: 30748299 to 30761176) (Data not shown), and is 
also mainly located within or overlapping the first exon of 
RNF40 (Homo sapiens ring finger protein 40, E3 ubiquitin 
protein ligase, NM_014771.3) (Figure 4B and Figure 5) 
in GenBank. Clone 31-2 consisted of 1104 nucleotides 
that did not match any known genes in GenBank (Figure 
3C). Clone 10-1 is mapped to chromosome 16p24.3, clone 
13-4 is mapped to chromosome 16p11.2, and clone 31-2 is 
mapped to chromosome 11q13.5.
Development of diagnostic SCAR markers
To generate stable diagnostic SCAR markers from 
our cloned RAPD fragments, three pairs of primers for 
semi-quantitative PCR (Table 3) and three pairs of primers 
for real-time PCR (Table 4) were designed and synthesized 
based on the cloned sequences. The semi-quantitative 
SCAR primer pairs were used to amplify ten samples of 
genomic DNA collected from the breast tumors of five 
breast cancer patients. Genomic DNA from non-tumor 
adjacent tissue was used to test for amplification marker-
specificity and to verify that the genomic DNA was over-
amplified in the tumor. The PCR results indicated that the 
products with expected size were observed in all samples by 
three SCAR markers (Figure 6A, 6B, and data not shown). 
SCAR markers BC10-1 and BC31-2 showed higher signals 
indicating that these SCAR markers have genomic DNA 
over-amplified in the tumor tissues (Figure 6). 
Real-time PCR was performed, including ten 
samples of women’s blood DNA, 22 samples of adjacent 
normal tissue DNA and 30 samples of breast tumor tissue 
DNA. The results of SCAR marker BC10-1 showed 
gradually increased levels from blood DNA to tumor 
DNA (p-value ≤ 0.05) (Figure 6C). SCAR marker BC13-
4 is present in increased levels in DNA from adjacent 
and tumor samples compared to blood DNA (p-value ≤ 
0.05), but no difference in levels between adjacent DNA 
and tumor DNA (Figure 6D). SCAR marker BC31-2 did 
not show increased levels between blood DNA and tumor 
DNA (data not shown)
DPEP1 mRNA expression in BC cells and 
invasive ductal carcinomas
The mRNA expression from the DPEP1 gene 
was performed by real-time PCR using RNA extracted 
from BC cell lines BT549, MDA-MB-231 and MDA-
MB-435, and non-tumorigenic mammary epithelial 
cell line MCF10A. We found that the level of DPEP1 
mRNA expression was lower in non-tumorigenic 
cell line MCF10A, but elevated in other BC cell lines 
(Figure 7A). To determine the DPEP1 levels in BC 
development, we collected invasive ductal carcinoma 
specimens from 33 human BC patients and 11 adjacent 
normal tissues with informed consent. Total RNAs were 
purified from each tumor tissue and the surrounding 
normal tissues followed by real-time PCR. Figure 7B 
shows that the mRNA levels of DPEP1 in BC tissues 
were significantly higher (11.6-fold) than that of the 
adjacent normal tissues.
Figure 1: Improved RAPD PCR from breast cancer tissues and their adjacent tissues. (A) High-GC primer FY-10. (B) High-
GC primer FY-13. (C) High -GC primer FY-31. Five pairs of genomic DNA from breast cancer tissues and their adjacent or surrounding 
normal tissues were subjected to improved RAPD amplification (high-GC RAMP-PCR). Lanes 1, 3, 5, 7 and 9 are DNA from breast cancer 
tissues (see Table 1). Lanes 2, 4, 6, 8 and 10 are their matched DNA from adjacent tissue. The blue arrows indicate bands that were excised 
for DNA cloning. Lane “M” shows the DL2000 DNA molecular weight marker (bp).
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Figure 2: Molecular cloning for RAPD products. (A) Agarose gel electrophoresis for RAPD DNA fragments 10, 13 and 31 derived 
from high-GC primers FY-10, FY-13 and FY-31, respectively. “T” indicates “pGM-T vector”. (B) Enzymatic identification of positive clones 
from RAPD fragment 10. (C) Enzymatic identification of positive clones from RAPD fragment 13. (D) Enzymatic identification of positive 
clones from RAPD fragment 31. Lane 1 contains undigested plasmid DNA; lane 2 contains plasmid DNA after EcoRI digestion. Clones 10-1, 
13-4 and 31-2 (blue text color) were selected for Sanger sequencing. Lane “M” contains the DL2000 DNA molecular weight marker (bp).
Figure 3: Results of Sanger-sequencing of the cloned DNA fragments. (A) The sequence of clone 10-1. (B) The sequence of 
clone 13-4. (C) The sequences of clone 31-2. 
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PHKG2 mRNA expression in BC cells
The mRNA expression from the PHKG2 gene was 
performed by real-time PCR using RNA extracted from 
breast cancer cell lines; we found that the level of PHKG2 
mRNA expression was lowest in the non-tumorigenic 
cell line MCF10A, but elevated in the other BC cell lines 
(Figure 7C).
DISCUSSION
The RAPD technique either alone or in 
combination with other technique is widely used 
for the genetic characterization of different plants, 
animals or other organisms, particularly in medicinal 
plants [17–19]. In a recent cancer study, RAPD was 
also used for screening genome-wide changes in DNA 
methylation, which was called Methylation Sensitive-
Random Amplified Polymorphic DNA-Polymerase 
Chain Reaction (MS-RAPD-PCR) [29]. Cancer patients 
are predisposed to fungal infections caused by Candida 
albicans, especially oral or respiratory tract candidiasis. 
Biernasiuk and colleagues [30] applied RAPD-PCR to 
successfully estimate genetic diversity of C. albicans 
isolated from the upper respiratory tract of patients 
with non-small cell lung cancer. However, there are 
some disadvantages to RAPD, like poor reproducibility 
and low yield of PCR products (low production). 
The resolution and production of RAPD are greatly 
increased by prolonging the RAMP time from the stage 
of annealing to extension in PCR [18, 19]. Recently, the 
technique was modified using high-GC content primers 
to improve the effectiveness of the RAPD method (high-
GC RAMP-PCR technique) [20]. This improved RAPD 
successfully increased the number of RAPD bands 
produced from a given DNA sample. Using improved 
RAPD with high-GC content primers, we found that the 
average number of bands per primer increased from 6.41 
to 15.04 in comparison to regular RAPD with standard 
primers. The average number of polymorphisms per 
primer was also increased from 4.647 to 10.22 [20]. 
Thus, we can produce more polymorphic bands using 
less RAPD primers. With these successes, we decided 
to apply this simple yet effective improved RAPD 
technique with high-GC primers to generate more 
fingerprints for detecting genomic alterations in human 
BC and developing diagnostic SCAR markers. High-GC 
primers FY-10, FY-13 and FY-32 were used to amplify 
genomic DNA successfully from five pairs of BC tissues 
and their adjacent tissues. Three different over-amplified 
bands were purified from the agarose gel, cloned and 
sequenced, and then used to successfully generate stable 
diagnostic SCAR markers BC10-1, BC13-4 and BC31-2.
Real-time PCR was performed using DNAs from 
bloods, tumor tissues and normal tissue adjacent to the 
tumor. SCAR marker BC10-1 results showed gradually 
increased levels from blood DNA to tumor DNA. SCAR 
marker BC13-4 are shown to have increased levels in both 
tumor tissues and normal tissues adjacent to the tumors 
compared to DNA from blood; however, there was no 
difference between DNA from tumor samples and adjacent 
tissues. SCAR marker BC31-2 did not show increased 
levels of tumor DNA compared to blood DNA. These 
results indicate that SCAR markers BC10-1 and BC13-4 
Figure 4: The Human genome locations of clones 10-1 and 13-4 with their partial cDNAs of DEPEP1 and RNF40, 
respectively.
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Figure 5: The sequence of clone 13-4 aligns with RNF40 cDNA. Depicted is the BLAST output showing alignment of the clone 
13-4 and RNF40 cDNA sequences.  The sequence of clone 13-4 showed 583bp (Plus strand) identity with the cDNA of RNF40 (minus strand).
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could be useful diagnostic markers of genomic instability 
or chromosome copy number variation in BC [14–16].
To note, the PHKG2 (Phosphorylase Kinase 
Subunit Gamma-2) gene, which encodes a subunit of 
phosphorylase kinase (Phk), is located close to SCAR 
marker BC13-4. Heritable deficiency of Phk, a regulatory 
enzyme of glycogen metabolism, is responsible for 25% 
of all cases of glycogen storage disease and occurs in 1 
in 100,000 births. Liver phosphorylase b kinase (PhK) 
deficiency (glycogen storage disease type IX), one of 
the most common causes of glycogen storage disease, is 
brought by mutations in the PHKA2, PHKB and PHKG2 
genes. Mutations in the testis/liver isoform of PHKG2, 
which leads to approximately 10–15% of cases, have 
been associated with autosomal liver glycogenosis in gsd 
rats and humans [31–33]. However, the role of PHKG2 in 
BC is unknown. Real-time PCR indicated that the level of 
mRNA expression for the PHKG2 gene was lowest in non-
tumorigenic BC cell line MCF10A, compared to elevated 
levels in all other tumorigenic BC cells tested. Of course, 
the levels of protein should be tested to further confirm 
their significance. Clone 10-1 was located and shown to 
overlap with DPEP1 gene which promoted metastasis in 
colon cancer [34–36] but inhibited tumor cell invasiveness 
in pancreatic ductal adenocarcinoma [37]. The role of 
DPEP1 in different types of cancer is controversial 
Figure 6: Genomic DNA amplification of SCAR markers BC10-1, BC13-4 and BC31-2 in breast cancer patients. (A) 
SCAR marker BC10-1 in five pairs of genomic DNA from breast cancer tissues and their adjacent tissues. (B) SCAR marker BC31-2 in 
five pairs of genomic DNA from breast cancer tissues and their adjacent tissues. Lanes 1, 3, 5, 7 and 9 contain DNA from breast cancer 
tissues (see Table 1). Lanes 2, 4, 6, 8 and 10 contain their matched adjacent tissue DNA. Blue arrows indicate the amplified band, whereas 
the stars “*” indicate the internal control. (C) Real-time PCR for SCAR marker BC10-1. (D) Real-time PCR for SCAR marker BC13-4. 
“Cancer”, breast cancer tissues; “Adjacent”, normal tissues adjacent to or surrounding the breast tumor; “Ctrl”, normal women blood DNA; 
“**”p value ≤ 0.05.
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[34–38]. Our results, for the first time, showed that the 
mRNA levels of DPEP1 in BC tissues were significantly 
higher (11.6-fold) than that of the adjacent normal tissues, 
which may play a role in promoting BC metastasis and 
invasiveness. Taken together, the DPEP1 and PHKG2 
gene may be prognostic targets, which would play a vital 
role in BC carcinogenesis. Further studies of how the 
DPEP1, PHKG2 and RNF40 function in BC progression 
and how they might be used for risk prediction and therapy 
are underway.
MATERIALS AND METHODS
Breast carcinoma DNA and RNA preparation
Human breast invasive ductal carcinoma specimens 
were collected from surgically removed tumor tissues 
at Southwest Medical University Affiliated Hospital in 
China with informed consent [39–42]. The protocol for 
human samples was approved by the Ethics Committee 
of Southwest Medical University. The patients were 
Chinese women, between 26 to 68 years old and did 
not receive preoperative radiotherapy or chemotherapy. 
The histopathologic profiles of the 5 breast carcinomas 
specimens for RAPD amplification are shown in Table 1. 
The cancer tissues and adjacent tissues or surrounding 
normal tissues were immediately frozen in liquid nitrogen 
and stored at −80ºC. DNA extraction from tissues was 
performed using the Proteinase K and phenol/chloroform 
method [40, 43–45]. Total RNA was isolated from cancer 
cells and tissues using the RNeasy Mini Kit (50) (Cat 
No.74104, QIAGEN) and stored at −80ºC. The RNA 
and DNA quality was determined by a 1% agarose gel 
electrophoresis and spectrophotometry. Genomic DNA 
Figure 7: Analysis of DPEP1 and PHKG2 expression in breast cancer cell lines and tissues. (A) DPEP1 gene expression in 
breast cancer cell lines. (B) DPEP1 gene expression in invasive ductal carcinoma specimens. (C) PHKG2 gene expression in breast cancer 
cell lines. “MDA231”, MDA-MB-231 cells; “MDA435”, MDA-MB-435 cells.
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from healthy women was also isolated from peripheral 
leukocytes or blood using the previously described method 
[43]. The final concentration of all DNA samples was 
adjusted to 20 ng/μl and stored at −20 ºC until use.
High-GC primers for RAPD
The 10-bp length oligos with high-GC contents (90% 
of G+C) were designed and synthesized at Beijing DNA 
chem. Biotechnology Co., Ltd (Beijing, China) and were 
as previously described [20]. The sequences of high-GC 
primers FY-10, FY-13 and FY-31 are presented in Table 2.
Amplification of DNA by high-GC RAPD PCR
All the contents of the PCR (10 μl total) were 
as follows: 1 μl of 2.5 μmol/L primers, 0.5 μl of DNA 
template (10 ng), 5 μl of 2×PCR Taq MasterMix (TianGen 
Biotech Co. Ltd., Beijing, China), 3.5 μl of deionized 
water. PCR conditions were as follows: initial denaturation 
at 95ºC for 90 s, followed by 40 cycles of 40 s at 94ºC, 
60 s at 36ºC, 90 s at 72 ºC, and final extension of 5 min 
at 72ºC. PCR amplification was executed in an “Applied 
Biosystems Veriti® 96-Well Thermal Cycler” (Life 
Technology, USA), and the RAMP time from annealing 
to extension with a RAMP rate for 5% (0.125 ºC/s) was 
used [20, 21].
Agarose gel electrophoresis 
The amplified RAPD-PCR products were resolved 
by electrophoresis on a 1.5% agarose gel in 1× TAE (Tris-
acetate-EDTA) buffer at 60 volts for 210 minutes at 4 ºC. 
To increase the resolution, the electrophoresis time was 
extended to 240 minutes at 60 volts at 4 ºC. Then, the 
gels were visualized by 0.5 μg/mL ethidium bromide 
(EB) staining, and the images were documented using 
the ChemiDoc XR (Bio-Rad, USA) [19, 43]. Bands 
with different intensity between BC tumors and adjacent 
normal tissues were selected for cloning. 
Molecular cloning of RAPD fragments from 
amplification by high-GC primers
Cloning of RAPD fragments was described 
previously [21, 23, 27, 28, 44]. Bands with differential 
amplification were excised from agarose gels and purified 
with a TIANgel Mini Purification Kit (DP209, China) 
according to the company provided protocol. Purified 
DNA fragments were ligated into pGM-T vector (VT202, 
Tiangen reagents, Beijing, China), and transformed into 
DH5α E. coli complement cells. The recombinant clones 
were selected on LB agar plates from blue and white 
colonies. The presence of right insert was verified by PCR 
by using T7/SP6 primer pairs, and EcoRI digestion from 
purified plasmids. The positive clones were selected for 
Sanger sequencing.
Development of diagnostic SCAR markers 
Homology searches within the human genome were 
performed using BLAST (http://www.ncbi.nlm.nih.gov/
BLAST/). The sequence of each cloned RAPD fragment 
was used to design pairs of SCAR primers using Primer 
3 software (http://frodo.wi.mit.edu/primer3). Sequences 
of the SCAR primers, amplification length and PCR 
conditions are shown in Table 3. Ten DNA samples, 
which we mentioned previously, were used as templates 
for PCR amplification for development of SCAR markers. 
The PCR reaction solution consisted of 5 μl 2×Taq PCR 
MasterMix, 1 μl of 2.5 μM each pair of SCAR primers and 
1 μl of genomic DNA (20ng), with a total volume of 10μl. 
Amplification reactions were performed with an initial 
pre-denaturation of 90 s at 95°C followed by 33 cycles 
of denaturation at 94°C for 40 s, annealing at 60°C for 
30 s, and extension at 72°C for 30 s. The final extension 
step was performed at 72°C for 5 min. The amplified 
PCR products were resolved by electrophoresis on a 1.5% 
agarose gel [19, 43]. For semi-quantitative genomic DNA 
PCR using SCAR markers, GAPDH gene served as a 
loading control.
Table 1: The histopathologic profiles of the 5 breast carcinomas specimens 
1 (TG53) 3 (TG55) 5 (TG57) 7 (TG59) 9 (TG62)
Histology Ductal Ductal Ductal Ductal Ductal
Diagnostic age 49 38 68 45 48
Stage T3 T4 T2 T2 T3
Grade II III II III III
Estrogen receptor +,90% − − − −
Progesterone receptor +,10% − − − −
HER-2 1+ 1+ 0 3+ 0
E-Cadherin + + + + +
p53 − +, 90% +, 40% +, 30% +, 60%
Ki-67 +, 40% +, 75% +, 70% +, 15% +, 50%
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Table 3: Sequences of SCAR primers, PCR product size (bp)
SCAR 5′-primer Sequence (5′-3′) 3′-primer Sequence (5′-3′) Size Tm (°C)
BC10-1 BC10-1L GATCACAGGCAGTCAGAGAGG BC10-1R CAGGCCACTTGAGACTCTCTG 590 60
BC31-2 BC31-2L ACAAACGGCCCCATTTCTTTG BC31-2R TTGGTGGTTGTGGTAGATGGG 512 60
GAPDH GAPDH5G ACCCAGAAGACTGTGGATGG GAPDH3G TGACAAAGTGGTCGTTGAGG 376 60
Note: SACR, sequence-characterized amplified region; bp, base pair.
Table 4: Sequences of real time PCR primers for SACR markers, probes
SCAR 5′-primer Sequence (5′-3′) 3′-primer Sequence (5′-3′) Probe
BC10-1 BC10-1L87 cccaggcagtagtgtagggta BC10-1R87 ccctcctctccatttctcaa 87
BC13-4 BC13-4L34 tctggcttcttcccaaacac BC13-4R34 cgcggtgtcagttactatgg 34
beta-actin Q-b-actin55LG  aagtcccttgccatcctaaaa Q-b-actin55RG atgctatcacctcccctgtg 55
Note: SACR, sequence-characterized amplified region.
Table 5: Sequences of real time PCR primers for PHKG2 and DPEP1 mRNA expression, probes
Gene 5′-primer Sequence (5′-3′) 3′-primer Sequence (5′-3′) Probe
PHKG2 Q-PHKG2-L2 caatatgcagatccgactttca Q-PHKG2-R2 ggggtcccacacaactctc 2
DPEP1 Q-DPEP1-13L  tgcactgcagacttctttcg Q-DPEP1-13R gccaggggaggtcattgt 13
18S 18S48R gcaattattccccatgaacg 18S48L gggacttaatcaacgcaagc 48
Table 2: The sequences of high-GC primers
Name Sequence (5′-3′)
FY-10 GCTCCCGCCG
FY-13 GCGTCCCGCC
FY-31 CGTGGCCCCG
Quantitative real-time PCR amplification
Three pairs of primers for real-time PCR of SCAR 
markers and β-actin were designed using software from 
assay design center of Roch (http://lifescience.roche.com/
shop/CategoryDisplay?catalogId=10001&tab=&identifier
=Universal+Probe+Library). Sequences of real-time PCR 
primers and probes for genomic DNA are shown in Table 4. 
Real-time PCR was performed using the FastStartUniversal 
Probe Master (Rox) (Cat No. 4914058001, Roch) and the 
StepOnePlus Real-Time PCR system (Applied Biosystems, 
USA) as described previously [39, 41, 42, 46–48]. The 
β-actin gene served as an internal control for normalizing 
the relative levels of SCAR markers.
Real-time PCR analysis of PHKG2 and DPEP1 
mRNA expression
The cDNA libraries were generated from 1 μg of 
total RNA using a reverse transcriptase kit (Invitrogen, 
USA). The method for real-time PCR was described 
previously [41, 42, 46–48]. Sequences of the primers and 
probes for human PHKG2 and DPEP1 mRNA are shown 
in Table 5. Levels of the 18S rRNA were measured in 
the same reaction for each sample to serve as an internal 
control for normalizing the relative mRNA levels of 
PHKG2 and DPEP1.
Statistical analysis
Student’s t-test was used to determine any significant 
differences. A p-value of less than 0.05 was considered 
to be significant for all tests. All the experiments were 
repeated thrice.
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